Spirogen Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $440M

  • Investors
  • 1

Spirogen General Information

Description

Operator of a clinical-stage biotechnology company intended to develop Deoxyribonucleic acid for minor groove binding molecules for the therapeutic treatment of cancers. The company specializes in The company developing a C2 unsaturated pyrrolobenzodiazepines dimer and a pyrrolobenzodiazepines dimer that is activated by hydrolysis and an achiral analog of duocarmycin that binds the A T rich deoxyribonucleic acid minor groove, thereby enabling clients to bind and cross-link specific sites of DNA of the cancer cell without distorting its DNA helix.

Contact Information

Formerly Known As
Spirogen Limited
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • The QMB Innovation centre
  • 42 New Road, London Borough of Tower Hamlets
  • London E1 2AX
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • The QMB Innovation centre
  • 42 New Road, London Borough of Tower Hamlets
  • London E1 2AX
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spirogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 15-Oct-2013 $440M Completed Clinical Trials - Phase 2
4. Later Stage VC 14-Oct-2009 Completed Clinical Trials - Phase 2
3. Early Stage VC 01-May-2003 Completed Product Development
2. Early Stage VC 01-Mar-2001 $1.45M $1.45M Completed Product Development
1. University Spin-Out 01-Jan-2000 Completed Startup
To view Spirogen’s complete valuation and funding history, request access »

Spirogen Patents

Spirogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210113587-A1 Pyrrolobenzodiazepine-antibody conjugates Inactive 25-Nov-2014
US-10188746-B2 Pyrrolobenzodiazepines and conjugates thereof Inactive 10-Sep-2014
US-20170340752-A1 Pyrrolobenzodiazepines and conjugates thereof Active 10-Sep-2014
JP-2017516766-A Pyrrolobenzodiazepine compounds for the treatment of lymphoma Pending 30-May-2014
AU-2015265638-A1 Pyrrolobenzodiazepine compounds for treating lymphoma Inactive 30-May-2014 C07D519/00
To view Spirogen’s complete patent history, request access »

Spirogen Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Auven Therapeutics PE/Buyout Minority
Bloomsbury Bioseed Fund Venture Capital Minority
Bloomsbury Investment Capital Corporation Minority
Cambridge Research BioVentures Venture Capital Minority
Cambridge Research and Innovation Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Spirogen FAQs

  • When was Spirogen founded?

    Spirogen was founded in 2000.

  • Where is Spirogen headquartered?

    Spirogen is headquartered in London, United Kingdom.

  • What industry is Spirogen in?

    Spirogen’s primary industry is Drug Discovery.

  • Is Spirogen a private or public company?

    Spirogen is a Private company.

  • What is the current valuation of Spirogen?

    The current valuation of Spirogen is .

  • What is Spirogen’s current revenue?

    The current revenue for Spirogen is .

  • How much funding has Spirogen raised over time?

    Spirogen has raised $16.5M.

  • Who are Spirogen’s investors?

    Auven Therapeutics, Bloomsbury Bioseed Fund, Bloomsbury Investment Capital, Cambridge Research BioVentures, and Cambridge Research and Innovation are 5 of 11 investors who have invested in Spirogen.

  • When was Spirogen acquired?

    Spirogen was acquired on 15-Oct-2013.

  • Who acquired Spirogen?

    Spirogen was acquired by MedImmune and AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process